Physician
Infectious Disease
Dr. Marnie L. Elizaga, MD
|
|
Give Review
Marnie L. Elizaga works in the field of Infectious Disease. She graduated from Albert Einstein College of Medicine of Yeshiva University. Marnie L. Elizaga, MD has written publications. She has 17 publications published with PubMed. The lastest paper is: 'A comparison of thermal responses of human and rodent cells.'
Publications
- Phase I/II Randomized Trial of Safety and Immunogenicity of LIPO-5 Alone, ALVAC-HIV (vCP1452) Alone, and ALVAC-HIV (vCP1452) Prime/LIPO-5 Boost in Healthy, HIV-1 Uninf...
- Specificity and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles.
- Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery.
- Prospective surveillance for cardiac adverse events in healthy adults receiving modified vaccinia ankara vaccines: a systematic review.
- Progress in the development of a preventive HIV-1 vaccine.
- Patients in long-term care facilities: a reservoir for vancomycin-resistant enterococci.
- Safety profile of recombinant canarypox HIV vaccines.
- Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.
- A comparison of thermal responses of human and rodent cells.
- Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults.
- A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers.
- A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects.
- Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial.
- HIV vaccine efficacy trials: towards the future of HIV prevention.
- Hepatitis C virus-specific cytolytic T cell responses after antiviral therapy.
- HIV-1 vaccination administered intramuscularly can induce both systemic and mucosal T cell immunity in HIV-1-uninfected individuals.
Schools
Albert Einstein College of Medicine of Yeshiva University
Northwestern University
McGaw Mc Of Northwestern University Meml Hospital
Rush Cook Cty
Doctors Specialties
- Infectious Disease Medicine
- Infectious Disease
Accepted Insurances
Education
-
Rush University Medical Center -
McGaw Medical Center of Northwestern University -
Albert Einstein College of Medicine of Yeshiva University
Helpful Reviews
Similar Doctors
|
|
Dr. Marc J. Gurwith, MD |